Mouse Genome Informatics
cn
    Msh2tm2.1Rak/Msh2tm3.1Rak
Tg(Vil-cre)20Syr/0

involves: 129/Sv * C57BL/6 * DBA/2 * SJL
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
       
tumorigenesis
• mice develop more and smaller tumors than in Msh2tm1Rak/Msh2tm2.1Wed Tg(Vil-cre)20Syr mice
• tumors respond to treatment with cisplatin or FOLFOX unlike tumors from Msh2tm1Rak/Msh2tm2.1Wed Tg(Vil-cre)20Syr mice
• beginning at 10 months, mice develop intestinal tumors
• by 13 months, 50% of mice develop intestinal tumors

homeostasis/metabolism
• tumor cells exhibit increased microsatellite instability compared with wild-type cells
• tumors respond to treatment with cisplatin or FOLFOX unlike tumors from Msh2tm1Rak/Msh2tm2.1Wed Tg(Vil-cre)20Syr mice
• FOLFOX-treated intestinal mucosa cells exhibit decreased apoptosis compared with similarly treated cells from Msh2tm2.1Wed homozygotes but increased compared with similarly treated cell from Msh2tm1Rak/Msh2tm2.1Wed Tg(Vil-cre)20Syr mice

cellular
• tumor cells exhibit increased microsatellite instability compared with wild-type cells

Mouse Models of Human Disease
OMIM IDRef(s)
Lynch Syndrome I 120435 J:161577